Abstract 3980
Background
RIB, an oral, selective CDK4/6 inhibitor, is approved for use in combination with endocrine therapy in women with HR+, HER2– ABC in the USA and EU. CompLEEment-1, an ongoing single-arm phase 3b trial, evaluated first-line RIB + LET with broad inclusion criteria to reflect a real-world HR+, HER2– ABC population. Here we report interim safety and efficacy in pts with VM or BOM.
Methods
Pts received RIB (600 mg/day, 3 weeks on/1 week off) + LET (2.5 mg/day). Men and premenopausal women also received goserelin (3.6 mg subcutaneously) or leuprolide (7.5 mg intramuscular injection) every 28 days. The primary outcome (safety) and key secondary outcomes (time to progression [TTP], overall response rate [ORR], and clinical benefit rate [CBR]) were reported for two subgroups: pts with VM and pts with BOM.
Results
Of the 3,246 pts, 1,983 (61.1%) had VM; among this group, 1,309 (66.0%) also had bone metastases. BOM were present in 706 pts (21.7%). At data cut-off (Aug 8, 2018), median duration of RIB exposure was 8.0 months in pts with VM and 8.8 months in pts with BOM. Median duration of study follow-up was 10.35 months. In pts with VM, the most common adverse events were neutropenia (57.2%), nausea (35.2%), and fatigue (22.5%); 12.5% discontinued due to AEs. Estimated 12-month event-free probability (EFP) in pts with VM was 63.1% (95% confidence interval [CI], 59.5-66.6%), ORR was 30.7% (95% CI, 28.4-33.1%) and CBR was 62.8% (95% CI, 60.3-65.2%). In pts with BOM, the most common AEs were neutropenia (57.8%), nausea (33.3%), and fatigue (21.5%); 11.8% discontinued due to AEs. The estimated 12-month EFP in the BOM subgroup was 82.8% (95% CI, 78.6-86.3%), ORR was 20.6% (95% CI, 14.8-27.3%), and CBR was 69.1% (95% CI, 61.7-75.9%).
Conclusions
Safety and efficacy outcomes in this post hoc analysis support the use of RIB + LET in pts with VM and BOM. Pts with BOM were less likely to have an objective tumor response but more likely to be progression free at 12 months, consistent with the more favorable prognosis of BOM compared with non-osseous metastases.
Clinical trial identification
NCT02941926.
Editorial acknowledgement
Medical editorial assistance was provided by Joe Hodgson of Healthcare Consultancy Group, LLC, and funded by Novartis Pharmaceuticals Corporation.
Legal entity responsible for the study
Novartis.
Funding
Novartis Pharmaceuticals.
Disclosure
M. De Laurentiis: Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Personal Fees, Speaker’s Honoraria, Advisory Board Honoraria: Pfizer; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Personal Fees, Speaker’s Honoraria, Advisory Board Honoraria: Novartis; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Personal Fees, Speaker’s Honoraria, Advisory Board Honoraria: Roche; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Personal Fees, Speaker’s Honoraria, Advisory Board Honoraria: Celgene; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Personal Fees, Speaker’s Honoraria, Advisory Board Honoraria: AstraZeneca; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Personal Fees, Speaker’s Honoraria, Advisory Board Honoraria: Eisai; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Personal Fees, Speaker’s Honoraria, Advisory Board Honoraria: Eli Lilly; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Personal Fees, Speaker’s Honoraria, Advisory Board Honoraria: Amgen. A. Ring: Honoraria (self), Advisory / Consultancy: Roche; Honoraria (self), Advisory / Consultancy: Genomic Health; Honoraria (self), Advisory / Consultancy: Eli Lilly; Honoraria (self), Advisory / Consultancy: Novartis; Honoraria (self), Advisory / Consultancy: Pfizer. M. Campone: Honoraria (institution), Advisory / Consultancy, Speaker Bureau / Expert testimony: Novartis; Advisory / Consultancy: Eli Lilly; Honoraria (institution), Advisory / Consultancy: Sanofi; Honoraria (institution), Advisory / Consultancy: Servier; Honoraria (institution), Advisory / Consultancy: Accord; Honoraria (institution), Advisory / Consultancy: Pfizer; Honoraria (institution), Advisory / Consultancy: Abbvie. T. Bachelot: Honoraria (self), Travel / Accommodation / Expenses: Roche; Honoraria (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: Novartis; Honoraria (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: AstraZeneca; Honoraria (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: Pfizer. W. Jacot: Honoraria (self): Pierre Fabre; Advisory / Consultancy: Pfizer; Advisory / Consultancy: Roche; Research grant / Funding (institution): AstraZeneca. P. Marchetti: Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): Novartis; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): BMS; Advisory / Consultancy, Speaker Bureau / Expert testimony: AstraZeneca; Advisory / Consultancy, Speaker Bureau / Expert testimony: Incyte; Advisory / Consultancy, Speaker Bureau / Expert testimony: Molteni; Advisory / Consultancy, Speaker Bureau / Expert testimony, Leadership role, Research grant / Funding (institution): Roche; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): MSD; Research grant / Funding (institution): Janssen. C. Timcheva: Advisory / Consultancy, Speaker Bureau / Expert testimony: Roche; Speaker Bureau / Expert testimony: AstraZeneca; Advisory / Consultancy, Speaker Bureau / Expert testimony: Novartis; Speaker Bureau / Expert testimony: MSD; Speaker Bureau / Expert testimony: Servie. A. Gombos: Research grant / Funding (institution): Novartis. All other authors have declared no conflicts of interest.
Resources from the same session
3034 - Efficacy and safety of neoadjuvant chemotherapy plus trastuzumab and pertuzumab in non-metastatic HER2-positive breast cancer in real life: NEOPEARL STUDY
Presenter: Maria Agnese Fabbri
Session: Poster Display session 2
Resources:
Abstract
4772 - Real world comparison of the impact of adjuvant capecitabine in women with high-risk triple-negative breast cancer after neoadjuvant chemotherapy
Presenter: Maysa Vilbert
Session: Poster Display session 2
Resources:
Abstract
5627 - Influence of age on the indication of adjuvant chemotherapy in early breast cancer using Oncotype DX. An analysis of 240 patients treated in the Institut Catala d’Oncologia (ICO) hospitals
Presenter: Sabela Recalde
Session: Poster Display session 2
Resources:
Abstract
3917 - Impact of delayed neoadjuvant systemic chemotherapy on survival among breast cancer patients
Presenter: Mariana Chavez Mac Gregor
Session: Poster Display session 2
Resources:
Abstract
2246 - Clinical Confirmation of Higher Exposure to Niraparib in Tumor vs Plasma in Patients With Breast Cancer
Presenter: Laura Spring
Session: Poster Display session 2
Resources:
Abstract
581 - The rationale for the effectiveness of systemic treatment of breast cancer depending on the body weight index
Presenter: Mohammad Hojouj
Session: Poster Display session 2
Resources:
Abstract
5327 - Response to neoadjuvant chemotherapy in HER2 non-overexpressing breast cancer subtypes
Presenter: Silvia Mihaela Ilie
Session: Poster Display session 2
Resources:
Abstract
3613 - Pre-specified interim analysis of the SAFE trial (NCT2236806): a 4-arm randomized, double-blind, controlled study evaluating the efficacy and safety of cardiotoxicity prevention in non-metastatic breast cancer patients treated with anthracyclines with or without trastuzumab.
Presenter: Lorenzo Livi
Session: Poster Display session 2
Resources:
Abstract
3736 - Safety of hypofractionated whole breast irradiation after conservative surgery for patients aged less than 60 years: a multi-center comparative study.
Presenter: Icro Meattini
Session: Poster Display session 2
Resources:
Abstract
5085 - Usefulness of NT-ProBNP as a biomarker of cardiotoxicity in breast cancer patients treated with trastuzumab
Presenter: Isabel Blancas López-Barajas
Session: Poster Display session 2
Resources:
Abstract